Use este identificador para citar ou linkar para este item: http://repositorio.ufc.br/handle/riufc/25128
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorKanchanatawan, Buranee-
dc.contributor.authorSirivichayakul, Sunee-
dc.contributor.authorCarvalho, André F.-
dc.contributor.authorAnderson, George-
dc.contributor.authorGalecki, Piotr-
dc.contributor.authorMaes, Michael-
dc.date.accessioned2017-08-28T11:28:13Z-
dc.date.available2017-08-28T11:28:13Z-
dc.date.issued2017-07-
dc.identifier.citationKANCHANATAWAN, B. et al. Depressive, anxiety and hypomanic symptoms in schizophrenia may be driven by tryptophan catabolite (TRYCAT) patterning of IgA and IgM responses directed to TRYCATs. Progress in Neuro-Psychopharmacology and Biological Psychiatry, v. xx, p. 1-12, jul. 2017.pt_BR
dc.identifier.issn0278-5846-
dc.identifier.urihttp://www.repositorio.ufc.br/handle/riufc/25128-
dc.language.isoenpt_BR
dc.publisherProgress in Neuro-Psychopharmacology and Biological Psychiatrypt_BR
dc.subjectDepressionpt_BR
dc.subjectAnxietypt_BR
dc.subjectAnsiedadept_BR
dc.subjectAracnoiditept_BR
dc.titleDepressive, anxiety and hypomanic symptoms in schizophrenia may be driven by tryptophan catabolite (TRYCAT) patterning of IgA and IgM responses directed to TRYCATspt_BR
dc.typeArtigo de Periódicopt_BR
dc.description.abstract-ptbrThe aim of this study was to delineate the associations between the tryptophan catabolite (TRYCAT) pathway and affective symptoms in schizophrenia. Towards this end we measured immunoglobulin (Ig)A and IgM responses to relatively noxious TRYCATs, namely quinolinic (QA), xanthurenic (XA), picolinic (PA) acid and 3-OHkynurenine (3HK), and generally protective TRYCATs, namely anthranilic (AA) and kynurenic (KA) acid in 80 patients with schizophrenia and 40 healthy controls. The Hamilton Rating Scale for Depression (HDRS) and anxiety (HAMA), Young Mania Rating Scale (YMRS) as well as the Positive and Negative Symptoms Scale of Schizophrenia (PANSS) were measured. Depression, anxiety and hypomanic as well as negative and positive symptoms were associated with increased IgA responses to PA. Increased IgA responses to XA were associated with anxiety, hypomanic and negative symptoms. Moreover, depressive, anxiety, hypomanic and negative symptoms were characterized by increased IgA responses to the noxious (XA +3HK+ QA+PA)/protective (AA +KA) TRYCAT ratio. All symptom dimensions were associated with increased IgM responses to QA, while depressive, anxiety, positive and negative symptoms were accompanied by lowered IgM responses to 3HK. Hypomanic symptoms were additionally accompanied by lowered IgM responses to AA, and negative symptoms by increased IgM responses to KA. In conclusion, both shared and distinct alterations in the activity of the TRYCAT pathway, as well as its regulatory factors and consequences, may underpin affective and classical psychotic symptoms of schizophrenia. Increased mucosa-generated production of noxious TRYCATs, especially PA, and specific changes in IgMmediated regulatory activities may be associated with the different symptom dimensions of schizophrenia.pt_BR
Aparece nas coleções:DMC - Artigos publicados em revistas científicas

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
2017_art_bkanchanatawan.pdf547,37 kBAdobe PDFVisualizar/Abrir
Mostrar registro simples do item Visualizar estatísticas


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.